Bank OZK Sells 449 Shares of Abbott Laboratories (NYSE:ABT)

Bank OZK trimmed its holdings in Abbott Laboratories (NYSE:ABT) by 2.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,091 shares of the healthcare product maker’s stock after selling 449 shares during the period. Bank OZK’s holdings in Abbott Laboratories were worth $1,881,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Zevenbergen Capital Investments LLC boosted its holdings in shares of Abbott Laboratories by 0.6% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 21,419 shares of the healthcare product maker’s stock worth $2,074,000 after buying an additional 130 shares during the period. Perigon Wealth Management LLC boosted its holdings in shares of Abbott Laboratories by 5.2% during the 4th quarter. Perigon Wealth Management LLC now owns 47,080 shares of the healthcare product maker’s stock worth $5,182,000 after buying an additional 2,317 shares during the period. Rockland Trust Co. boosted its holdings in Abbott Laboratories by 1.5% in the 3rd quarter. Rockland Trust Co. now owns 91,868 shares of the healthcare product maker’s stock valued at $8,897,000 after purchasing an additional 1,343 shares during the period. VisionPoint Advisory Group LLC boosted its holdings in Abbott Laboratories by 7.4% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 3,106 shares of the healthcare product maker’s stock valued at $301,000 after purchasing an additional 215 shares during the period. Finally, Gradient Investments LLC boosted its holdings in Abbott Laboratories by 4.7% in the 4th quarter. Gradient Investments LLC now owns 257,508 shares of the healthcare product maker’s stock valued at $28,344,000 after purchasing an additional 11,508 shares during the period. 75.18% of the stock is owned by institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now owns 65,027 shares in the company, valued at approximately $7,315,537.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Daniel Gesua Sive Salvadori sold 963 shares of Abbott Laboratories stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $114,115.50. Following the completion of the sale, the executive vice president now owns 125,697 shares in the company, valued at approximately $14,895,094.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Andrea F. Wainer sold 42,500 shares of Abbott Laboratories stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the sale, the executive vice president now owns 65,027 shares of the company’s stock, valued at approximately $7,315,537.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,435 shares of company stock worth $6,451,298. 1.10% of the stock is currently owned by corporate insiders.

Abbott Laboratories Price Performance

ABT stock traded up $0.67 during trading on Friday, hitting $107.53. 3,575,566 shares of the stock traded hands, compared to its average volume of 5,219,304. Abbott Laboratories has a one year low of $89.67 and a one year high of $121.64. The stock has a market cap of $186.58 billion, a price-to-earnings ratio of 33.50, a P/E/G ratio of 2.57 and a beta of 0.74. The company has a 50 day simple moving average of $113.64 and a 200 day simple moving average of $108.03. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. The firm had revenue of $9.96 billion during the quarter, compared to the consensus estimate of $9.88 billion. During the same period last year, the firm posted $1.03 EPS. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. Equities analysts expect that Abbott Laboratories will post 4.62 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 2.05%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s payout ratio is presently 68.54%.

Analyst Ratings Changes

ABT has been the subject of a number of research reports. Evercore ISI increased their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Barclays reduced their price target on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a report on Monday, April 22nd. Royal Bank of Canada reduced their price objective on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday, April 18th. Citigroup raised their price objective on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, Raymond James reaffirmed a “buy” rating and set a $124.00 price objective on shares of Abbott Laboratories in a report on Wednesday. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $121.50.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.